Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Maintenance Organizations | 8 | 2007 | 642 | 0.370 |
Why?
|
| Treatment Refusal | 5 | 2008 | 421 | 0.250 |
Why?
|
| Patient Compliance | 7 | 2009 | 2684 | 0.240 |
Why?
|
| Drug Utilization | 7 | 2008 | 1183 | 0.220 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2971 | 0.220 |
Why?
|
| Benzodiazepines | 5 | 2007 | 1101 | 0.180 |
Why?
|
| RNA Polymerase II | 1 | 2003 | 551 | 0.160 |
Why?
|
| Drug Therapy | 3 | 2008 | 497 | 0.160 |
Why?
|
| Drug Prescriptions | 5 | 2008 | 1637 | 0.160 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2007 | 434 | 0.150 |
Why?
|
| Models, Statistical | 2 | 2008 | 5102 | 0.150 |
Why?
|
| Research Design | 3 | 2008 | 5987 | 0.140 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2003 | 852 | 0.140 |
Why?
|
| Drug Costs | 4 | 2008 | 1105 | 0.130 |
Why?
|
| Legislation, Drug | 2 | 2007 | 206 | 0.120 |
Why?
|
| Antidepressive Agents | 4 | 2007 | 2838 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 2 | 2007 | 390 | 0.120 |
Why?
|
| Medical Indigency | 3 | 2008 | 64 | 0.120 |
Why?
|
| Medicare Part D | 2 | 2008 | 328 | 0.110 |
Why?
|
| Prescriptions | 2 | 2008 | 387 | 0.110 |
Why?
|
| Postnatal Care | 3 | 2004 | 236 | 0.110 |
Why?
|
| Health Policy | 5 | 2008 | 2661 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 5853 | 0.100 |
Why?
|
| Diabetes Mellitus | 6 | 2009 | 5751 | 0.090 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2007 | 336 | 0.090 |
Why?
|
| Hypoglycemic Agents | 5 | 2009 | 2872 | 0.090 |
Why?
|
| Medicaid | 6 | 2008 | 2736 | 0.080 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 95 | 0.080 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 120 | 0.070 |
Why?
|
| Hip Fractures | 2 | 2007 | 955 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2008 | 623 | 0.070 |
Why?
|
| Marketing | 1 | 2008 | 212 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2008 | 6459 | 0.070 |
Why?
|
| Length of Stay | 3 | 2004 | 6309 | 0.070 |
Why?
|
| Depressive Disorder | 3 | 2007 | 3748 | 0.060 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 166 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 430 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.060 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 71 | 0.060 |
Why?
|
| Pirenzepine | 1 | 2003 | 115 | 0.060 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2003 | 43 | 0.060 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2003 | 43 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2003 | 66 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2006 | 502 | 0.050 |
Why?
|
| Antipsychotic Agents | 2 | 2008 | 3057 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 245 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2003 | 287 | 0.050 |
Why?
|
| Histidine | 1 | 2003 | 313 | 0.050 |
Why?
|
| Haloperidol | 1 | 2003 | 397 | 0.050 |
Why?
|
| Patient Discharge | 3 | 2003 | 3313 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1157 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2006 | 694 | 0.050 |
Why?
|
| Infant Care | 1 | 2002 | 183 | 0.050 |
Why?
|
| Medicare | 3 | 2008 | 6566 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 1161 | 0.050 |
Why?
|
| Alanine | 1 | 2003 | 572 | 0.050 |
Why?
|
| Disabled Persons | 2 | 2007 | 1212 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2008 | 12245 | 0.050 |
Why?
|
| Massachusetts | 7 | 2007 | 8663 | 0.050 |
Why?
|
| Warfarin | 1 | 2008 | 1496 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 671 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2008 | 11725 | 0.040 |
Why?
|
| Serine | 1 | 2003 | 826 | 0.040 |
Why?
|
| New York | 3 | 2007 | 886 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2004 | 859 | 0.040 |
Why?
|
| Breast Feeding | 2 | 2004 | 1338 | 0.040 |
Why?
|
| Plasmids | 1 | 2003 | 2307 | 0.040 |
Why?
|
| Aftercare | 1 | 2003 | 866 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2003 | 1169 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2004 | 1149 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 2540 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1783 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2003 | 3128 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 3846 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 2278 | 0.030 |
Why?
|
| Disease Management | 1 | 2006 | 2459 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2003 | 5179 | 0.030 |
Why?
|
| New Jersey | 2 | 2007 | 290 | 0.030 |
Why?
|
| Transfection | 1 | 2003 | 5892 | 0.030 |
Why?
|
| Humans | 33 | 2009 | 744343 | 0.030 |
Why?
|
| Health Expenditures | 2 | 2008 | 2348 | 0.030 |
Why?
|
| Male | 24 | 2009 | 350118 | 0.030 |
Why?
|
| Binding Sites | 1 | 2003 | 6114 | 0.030 |
Why?
|
| Aged | 16 | 2009 | 163280 | 0.030 |
Why?
|
| Health Care Surveys | 3 | 2007 | 2453 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 1419 | 0.030 |
Why?
|
| Middle Aged | 18 | 2009 | 213383 | 0.030 |
Why?
|
| Female | 25 | 2009 | 380194 | 0.030 |
Why?
|
| Socioeconomic Factors | 4 | 2008 | 7785 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2008 | 4599 | 0.030 |
Why?
|
| State Health Plans | 2 | 2006 | 216 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2003 | 3494 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2004 | 1901 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2003 | 8436 | 0.030 |
Why?
|
| Anxiety | 1 | 2006 | 4297 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 4986 | 0.020 |
Why?
|
| Demography | 2 | 2006 | 1656 | 0.020 |
Why?
|
| Peptides | 1 | 2003 | 4409 | 0.020 |
Why?
|
| Protein Binding | 1 | 2003 | 9386 | 0.020 |
Why?
|
| Adult | 15 | 2009 | 214055 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2009 | 3913 | 0.020 |
Why?
|
| Longitudinal Studies | 4 | 2009 | 13989 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2006 | 4371 | 0.020 |
Why?
|
| United States | 9 | 2008 | 69872 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2006 | 3674 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 6882 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 7722 | 0.020 |
Why?
|
| New Hampshire | 1 | 2008 | 172 | 0.020 |
Why?
|
| Maine | 1 | 2008 | 139 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 467 | 0.020 |
Why?
|
| Diabetes Complications | 2 | 2006 | 1359 | 0.020 |
Why?
|
| Cohort Studies | 5 | 2008 | 40561 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2006 | 47 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2003 | 5027 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 4644 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2006 | 103 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 4933 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2008 | 308 | 0.020 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 57776 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 119 | 0.020 |
Why?
|
| Self Administration | 1 | 2006 | 385 | 0.020 |
Why?
|
| Oxycodone | 1 | 2006 | 153 | 0.020 |
Why?
|
| Methadone | 1 | 2006 | 306 | 0.020 |
Why?
|
| Leucine Zippers | 1 | 2004 | 117 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 12208 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2004 | 100 | 0.010 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2006 | 245 | 0.010 |
Why?
|
| Age Factors | 3 | 2007 | 18370 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 154 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 720 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 661 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10943 | 0.010 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 352 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 657 | 0.010 |
Why?
|
| Logistic Models | 2 | 2008 | 13408 | 0.010 |
Why?
|
| Retrospective Studies | 5 | 2009 | 77449 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2007 | 921 | 0.010 |
Why?
|
| Personality Inventory | 1 | 2003 | 1030 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2297 | 0.010 |
Why?
|
| Comorbidity | 2 | 2007 | 10388 | 0.010 |
Why?
|
| Phototherapy | 1 | 2004 | 377 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 1723 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 347 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 783 | 0.010 |
Why?
|
| Cost Control | 1 | 2002 | 624 | 0.010 |
Why?
|
| Prevalence | 2 | 2007 | 15226 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2004 | 839 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 1372 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 1791 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2004 | 25625 | 0.010 |
Why?
|
| Psychometrics | 1 | 2008 | 3002 | 0.010 |
Why?
|
| Data Collection | 1 | 2008 | 3341 | 0.010 |
Why?
|
| Mutation | 1 | 2003 | 29786 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4751 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 490 | 0.010 |
Why?
|
| Adolescent | 4 | 2008 | 85781 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4037 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2003 | 455 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 2488 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4669 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6386 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 2356 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2716 | 0.010 |
Why?
|
| Home Care Services | 1 | 2002 | 606 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 1788 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2004 | 1373 | 0.010 |
Why?
|
| Psychiatry | 1 | 2007 | 1695 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 168757 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 25043 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 3229 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3589 | 0.010 |
Why?
|
| Social Class | 1 | 2003 | 1999 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12354 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 6038 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 4386 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2003 | 2050 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 7149 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 39050 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2003 | 2616 | 0.010 |
Why?
|
| Insulin | 1 | 2007 | 6580 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4479 | 0.010 |
Why?
|
| Young Adult | 2 | 2008 | 56430 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 9146 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9313 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3255 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 21746 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 14557 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2007 | 4558 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2788 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10481 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 5137 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 19905 | 0.010 |
Why?
|
| Health Status | 1 | 2003 | 4034 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12026 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 16689 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 12720 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2002 | 3114 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 20947 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 16365 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 21827 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18029 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 7659 | 0.000 |
Why?
|
| Hospitalization | 1 | 2002 | 10262 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 23403 | 0.000 |
Why?
|
| Child | 1 | 2008 | 77709 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 81183 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 63114 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 72290 | 0.000 |
Why?
|
| Neoplasms | 1 | 2003 | 21683 | 0.000 |
Why?
|
Concepts
(209)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_